866-997-4948(US-Canada Toll Free)

Published on : Jun 06, 2017

Albany, New York, June 06, 2017: The report, titled “ Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review, 2017,” has been prepared to act as a credible business document for stakeholders connected to the value chain such as pharmaceuticals manufacturers, research and academic institutes, hospitals and clinics, and contract manufacturers. 

The aim of the report is to represent an overview of all products that are under development for each indication, analyze the companies and research institutes that are operating in the pipeline, and find the composition of the pipeline on the basis of molecular target, molecule type, route of administration, and mechanism of action.

A comprehensive analysis of therapeutics that are under development and corresponding key players involved have been provided by the report. The sections of the therapeutic developed covered by the report includes chemotherapy induced neutropenia, chemotherapy induced nausea and vomiting, chemotherapy induced peripheral neuropathy, and chemotherapy induced anemia. Some of the important dormant and discontinued projects have also been analyzed by the report, and their implications on the overall toxicity drug development market have been suggested.

The report has observed that all the above mentioned side effects of cancer chemotherapy treatment result in significantly poor quality of life for the patients. For instance, chemotherapy induced nausea and CINV or vomiting and chemotherapy-induced neutropenia are common side effects, wherein symptoms include headaches, weakness, severe fatigue, anxiety, shortness of breath, lack of energy, rapid heart rate or palpitations, pale appearance, abdominal pain, and chest pain dizziness.

Click to get more details with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=1070458

The symptoms of chemotherapy-induced anemia can be pale appearance, cognitive impairment, loss of sexual desire, headaches, lack of energy, persistent fatigue, chest pain dizziness, anxiety, severe weakness, rapid heart rate or palpitations, and depression. Moreover, chemotherapy-induced peripheral neuropathy (CIPN) is another side effect of cancer treatment wherein a patient experiencing muscle weakness, burning, pain, tingling, constipation, balance problems, and blood pressure changes.

The size of pipelines studied by this report, ranges from 41 in chemotherapy-induced neutropenia and CIPN and 16 in chemotherapy-induced anemia. Although several of these targets are neurotransmitter receptors, diverse range targets have been studied in CIPN and CINV. To complete an in-depth study, the report also explores chemotherapy-induced neutropenia and anemia that are limited in terms of molecular targets.

The report detects the companies that are most active in the pipeline for toxicology therapeutics, finds the most prominent pharmaceutical approaches at each stage of the pipeline and indication. The role of universities and research institutes in these pipelines in comparison to pharmaceutical companies has been evaluated by the report.

Some of the leading companies involved in toxicity drug development market are Dr. Reddy's Laboratories Ltd, Chong Kun Dang Pharmaceutical Corp, Biogenomics Ltd, Bolder Biotechnology Inc, Cellerant Therapeutics Inc, Pfizer Inc, Genexine Inc, Biocon Ltd, Hanmi Pharmaceuticals Co Ltd, Cinfa Biotech SL, Gene Techno Science Co Ltd, Generon (Shanghai) Corp Ltd, GlycoMimetics Inc, Pfenex Inc, Mycenax Biotech Inc, and Myelo Therapeutics GmbH.

To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on sales@researchmoz.us